RxDoctor Payments Data

Khaled Rabadi, MD

Internal Medicine · Grand Forks, NDNPI 1639180425

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $311 of the $425 with a category attached, or 73.3%. 14 manufacturers reported payments, led by Mallinckrodt Enterprises LLC at 26.2% of the total. Reporting peaked in 2019 at $342 and has fallen 91.9% since, to $28 in 2022.

$425in general payments, 2019–2025

Across 25 payments — averaging $16.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Enterprises LLC$111
  • AstraZeneca$85
  • Merck$47
  • Dexcom, Inc.$32
  • Takeda Pharmaceuticals U.S.A., Inc.$28
  • Johnson & Johnson$28
  • plus $92 from 8 others

What the payments were for

  • Food & beverage$31173%
  • Education$11327%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$425 in reported general payments places this provider in the 70th percentile of 159 internal medicine providers in North Dakota.

See all internal medicine providers in North Dakota

Medicare billing

Part B allowed, 2024
$669,380
Medicare patients
694
Services billed
14,919

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide124$137,084
EliquisApixaban118$92,258
JanuviaSitagliptin Phosphate72$58,049
Novolog FlexpenInsulin Aspart80$42,868
XareltoRivaroxaban27$29,717
Tresiba Flextouch U-100Insulin Degludec29$27,810
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog61$27,805
EntrestoSacubitril/Valsartan49$24,516
Labetalol Hcl371$21,662
Fiasp FlextouchInsulin Aspart (Niacinamide)23$20,257
Nifedipine ErNifedipine542$19,077
ProsolParenteral Amino Acid 20% No.1104$18,289
Humalog Kwikpen U-100Insulin Lispro59$14,377
JardianceEmpagliflozin14$14,318
Lantus SolostarInsulin Glargine,hum.Rec.Anlog88$10,116

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$12$137,084124 claims
MerckJanuvia$47$58,04972 claims
Johnson & JohnsonXarelto$28$29,71727 claims
AstraZenecaSymbicort$85$3,21815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 159 internal medicine providers in North Dakota.

Other internal medicine in Grand Forks

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →